The FDA has approved Moderna’s mRNA-based influenza vaccine, the first flu shot to use this technology. The approval follows standard regulatory review and shifts from prior manufacturing methods that require six to eight months. Available data on annual flu burden and long-term performance of the new product remain limited to the cited sources.